Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization

References

• Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864–71
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464–70
   PubMed Web of Science ®Google Scholar
• Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652–60
   PubMed Web of Science ®Google Scholar
• Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003; 9: 12–8
   PubMed Web of Science ®Google Scholar
• Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797–805
   PubMed Web of Science ®Google Scholar
• Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther 2003; 17: 1563–9
   PubMed Web of Science ®Google Scholar
• Brown DB, Fundakowski CE, Lisker-Melman M, Crippin JS, Pilgram TK, Chapman W, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15: 1209–18
   PubMed Web of Science ®Google Scholar
• Georgiades CS, Liapi E, Frangakis C, Park JU, Kim HW, Hong K, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 2006; 17: 1619–24
   PubMedGoogle Scholar
• Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004; 10: 88–98
   PubMedGoogle Scholar
• Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918–28
   PubMed Web of Science ®Google Scholar
• CLIP A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751–5.
   PubMed Web of Science ®Google Scholar
• CLIP Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 2000;31:840–5.
   PubMedGoogle Scholar
• Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207–15
   PubMed Web of Science ®Google Scholar
• Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215–9
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36
   PubMed Web of Science ®Google Scholar
• Greene FL, American Joint Committee on Cancer American Cancer Society. AJCC cancer staging manual, 6th ed. New York: Springer; 2002.
   Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   Web of Science ®Google Scholar
• Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187–96
   PubMed Web of Science ®Google Scholar
• Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 2006; 101: 1516–23
   PubMed Web of Science ®Google Scholar
• D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–31
   PubMed Web of Science ®Google Scholar
• Freeman RB, Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851–8
   PubMed Web of Science ®Google Scholar
• Jang BK, Lee SH, Chung WJ, Park KS, Cho KB, Hwang JS, et al. Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J Hepatol 2008; 14: 168–77
   PubMedGoogle Scholar
• Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32–9
   PubMed Web of Science ®Google Scholar
• Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802–10
   PubMed Web of Science ®Google Scholar
• Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336–43
   PubMed Web of Science ®Google Scholar
• Londono MC, Cardenas A, Guevara M, Quinto L, de Las Heras D, Navasa M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56: 1283–90
   PubMed Web of Science ®Google Scholar
• Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323–8
   PubMedGoogle Scholar
• Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69–89.
   PubMed Web of Science ®Google Scholar
• Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229–36
   PubMed Web of Science ®Google Scholar
• Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000; 32: 605–10
   PubMedGoogle Scholar
• Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46–52
   PubMed Web of Science ®Google Scholar
• Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wiesner R, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 2004; 4: 1798–804
   PubMed Web of Science ®Google Scholar
• Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005; 92: 1862–8
   PubMed Web of Science ®Google Scholar
• Chok KS, Ng KK, Poon RT, Lam CM, Yuen J, Tso WK, et al. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 2006; 141: 1231–6
   PubMedGoogle Scholar
• Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461–9
   PubMed Web of Science ®Google Scholar
• Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, et al. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther 2007; 26: 393–400
   PubMed Web of Science ®Google Scholar
• Narvaez-Lugo J, Caceres WW, Toro DH, Perez-Gonzalez MR, Almodovar AA, Maldonado-Mercado AM, et al. Transcatheter arterial chemoembolization and percutaneous ethanol injection for hepatocellular carcinoma: a retrospective review of the Veterans Affairs Caribbean Healthcare System. Cancer Control 2008; 15: 80–5
   PubMedGoogle Scholar
• Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, et al. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008; 98: 1161–5
   PubMedGoogle Scholar
• Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16: 1661–6
   PubMedGoogle Scholar